{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:34:32Z","timestamp":1648766072396},"reference-count":5,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","aaojournal.org","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ophtha.2018.03.022","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T06:17:38Z","timestamp":1532326658000},"page":"e56-e57","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Vogel et\u00a0al.: Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity (Ophthalmology. 2018;125:444-452)"],"prefix":"10.1016","volume":"125","author":[{"given":"G\u00f6khan","family":"Pekel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evre","family":"Pekel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.03.022_bib1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ophtha.2017.09.020","article-title":"Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity","volume":"125","author":"Vogel","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.03.022_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","article-title":"Advances in understanding and management of retinopathy of prematurity","volume":"62","author":"Hartnett","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2018.03.022_bib3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1080\/02713683.2016.1264607","article-title":"Comparison of intravitreal bevacizumab, intravitreal ranibizumab and laser photocoagulation for treatment of type 1 retinopathy of prematurity in Turkish preterm children","volume":"42","author":"Kabata\u015f","year":"2017","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2018.03.022_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"Vanderveen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2018.03.022_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018302215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018302215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T04:26:11Z","timestamp":1571631971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018302215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0161642018302215"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.022","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Vogel et\u00a0al.: Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity (Ophthalmology. 2018;125:444-452)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}